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Abstract
The Vpx protein of human immunodeficiency virus type 2 (HIV-2) is a viral accessory protein related to, but distinct from, the Vpr
protein of HIV-1. Vpx is packaged into virions and, as a component of the viral preintegration complex (PIC), Vpx is required for efficient
virus replication in nondividing cells. Therefore, the localization of Vpx in cells is dynamic and dependent upon discrete domains of the
protein. Expressed in the absence of other viral proteins, Vpx localizes to the nucleus of cells. However, if expressed with the Gag protein
of HIV-2, Vpx localizes to the plasma membrane of cells. To further understand the regulation of Vpx localization, we fused regions of Vpx
to -galactosidase to identify regions of the protein sufficient to mediate nuclear localization. The minimal transferable region of Vpx that
conferred nuclear localization in these assays was aa 65 to 72. Alanine substitution of K68 and R70 in a GFP-Vpx construct abolished nuclear
localization, suggesting that the basic residues in this region are important for nuclear import. Analysis of the membrane transport of several
GFP-Vpx alanine mutants demonstrated that while separable, the domains of Vpx required for nuclear localization are not distinct from the
domains required for membrane transport. The results of heterokaryon shuttling assays indicated that Vpx is not a shuttling protein; however,
HIV-2 Vpr did shuttle similar to HIV-1 Vpr.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
Productive infection of nondividing cells by the human
and simian immunodeficiency viruses (HIV and SIV, re-
spectively) requires active nuclear transport of the viral
DNA across the host cell nuclear membrane prior to viral
dsDNA integration into the host genome. This task is ac-
complished through the viral preintegration complex (PIC),
a nucleoprotein complex composed of cellular and viral
components (reviewed in Fouchier and Malim, 1999). The
viral components include the dsDNA, reverse transcriptase,
matrix, nucleocapsid, integrase, and Vpr (HIV-1) or Vpx
(HIV-2/SIV) proteins (Bukrinsky et al., 1993b; Farnet and
Haseltine, 1991; Hansen and Bushman, 1997; Heinzinger et
al., 1994; Miller et al., 1997). The matrix, integrase, Vpr,
and Vpx proteins have each been identified as having karyo-
philic properties (Bukrinsky et al., 1993a; Gallay et al.,
1997; Heinzinger et al., 1994; Pancio et al., 2000). Although
each of these proteins has been demonstrated to be a crucial
regulator of nuclear import of the PIC, it remains unclear as
to the exact contribution each protein plays. In addition, the
central DNA flap has also been shown to be an important
signal for nuclear entry of the PIC (Zennou et al., 2000).
There is significant sequence homology among the Vpr
and Vpx proteins (Tristem et al., 1990, 1998). Both are of
similar size (14–17 kDa), are packaged in virions, and
possess similar functions (Fletcher et al., 1996). The Vpr
protein of HIV-1 has been extensively studied and demon-
strated to possess at least two discrete functions. Early in
virus replication, Vpr mediates infection of nondividing
cells by directing nuclear import of viral PICs (Popov et al.,
1998). Vpr contains two discrete NLSs that directly target to
the nuclear pore complex (NPC) and facilitate entry into the
nucleus (Jenkins et al., 1998). It has also been proposed that
Vpr-induced herniation of the nuclear envelope structure
may facilitate PIC import (De Noronha et al., 2001). Vpr
has also been demonstrated to cause G2 cell-cycle arrest of
proliferating cells (Goh et al., 1994). This effect may con-
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tribute to increased virus production since viral transcription
is most active during this phase of the cell cycle (Goh et al.,
1994). Interestingly, two nonarresting mutants of Vpr failed
to alter nuclear membrane morphology, suggesting that nu-
clear membrane disruption may contribute to G2 cell-cycle
arrest (De Noronha et al., 2001). HIV-1 Vpr has also been
demonstrated to be a shuttling protein capable of nuclear
import and export (Sherman et al., 2001). While the role of
shuttling on Vpr function has not been elucidated, it has
been shown to be dispensible for packaging of Vpr into
virions (Jenkins et al., 2001). Mutation of the nuclear export
signal of Vpr abolished Vpr-mediated nuclear membrane
herniation (De Noronha et al., 2001). Together, these results
suggest that Vpr shuttling may be important for Vpr-medi-
ated cell-cycle arrest.
Unlike HIV-1, HIV-2 contains both the vpr and the vpx
genes, each with discrete functions (Fletcher et al., 1996).
HIV-2 Vpr has been demonstrated to arrest cells in G2, but
plays no role in nuclear import of the PIC (Fletcher et al.,
1996). Vpx is a 17-kDa, 112 amino acid (aa) protein that is
packaged into virions but is not crucial for virion morphol-
ogy. HIV-2 Vpx is necessary for efficient replication in
nondividing cells (Pancio et al., 2000). As a component of
the HIV-2 PIC, Vpx, similar to HIV-1 Vpr, has been shown
to be necessary and sufficient for nuclear translocation of
the PIC, but plays no role in integration (Hansen and Bush-
man, 1997). As such, Vpx plays an important role in the
early steps of virus replication. Indeed, SIVsm Vpx has been
demonstrated to be required for virus dissemination and
pathogenesis in vivo (Hirsch et al., 1998). This may be due
to the nuclear import role of Vpx in allowing infection of
quiescent cells. The cellular localization of Vpx is dynamic
and dependent upon discrete domains within the protein.
Expressed in the absence of other HIV-2 components, Vpx
exhibits a predominantly nuclear localization, with limited
perinuclear localization (Mahalingam et al., 2001; Pancio et
al., 2000). However, expressed in the presence of HIV-2
Gag, Vpx is observed to localize to the plasma membrane
(Pancio et al., 2000). The interaction of Vpx and Gag
facilitates the packaging of Vpx during virus assembly.
Plasma membrane localization and packaging of Vpx are
mediated through the interaction of aa 81–86 of Vpx with
aa 15–40 of the HIV-2 p6 protein (Jin et al., 2001; Selig et
al., 1999).
Previous work suggested that the C-terminus of Vpx
contained an NLS (Pancio et al., 2000). These studies dem-
onstrated that deletion of the 11 C-terminal aa of Vpx
abolished nuclear localization of a GFP-Vpx fusion, re-
sulted in decreased nuclear import of viral PICs, and de-
creased virus replication in macrophage cultures. These
studies were confirmed in another article (Mahalingam et
al., 2001). Using GFP fusion proteins, this study also iden-
tified an NLS in a broad region of Vpx (aa 60–85) (Ma-
halingam et al., 2001). Several mutations in this region,
including both charged (H82) and hydrophobic residues
(L74 and L75), abolished nuclear localization. Other C-
terminal mutations were also found to be deleterious to Vpx
nuclear localization, further suggesting the C-terminus of
Vpx (aa 60–112) is required for full nuclear targeting ca-
pability. Here we report that aa 65 to 72 is the minimal
transferable region of Vpx that contains nuclear localization
properties. Furthermore mutation of basic residues in this
region disrupted nuclear localization of a GFP–Vpx fusion,
but was not deleterious to membrane transport in the pres-
ence of Gag- Pol. These results demonstrate that the nuclear
localization and membrane transport of Vpx are separable.
However, other mutations C-terminal to this region in Vpx
disrupted both nuclear localization and membrane transport,
indicating that the requirements for both functions are not
discrete. Defining the mechanism of Vpx nuclear import
may lead to the development of therapeutic interventions at
early stages of virus replication.
Results
Construction and expression of lacZ–vpx fusions
Published reports conflict as to the exact size limit
(40–60 kDa) of proteins capable of passive diffusion be-
tween the nucleus and cytoplasm of cells. Therefore, to
identify the domain(s) of Vpx that facilitates nuclear local-
ization, we constructed a series of lacZ–vpx fusions. The
use of -galactosidase (-gal) as a fusion partner for the
Vpx fragments resulted in proteins greater than 100 kDa in
Fig. 1. Amino acid sequence of HIV-2 ROD Vpx and expression of
-gal–Vpx fusion proteins. (A) Amino acid sequence of HIV-2 ROD Vpx.
(B) Western blot of lysates from 293T cells transiently transfected with
indicated lacZ–vpx fusions (numbers indicate aa of Vpx present in fusion).
Fusion proteins were detected using a monoclonal anti--gal antibody
followed by an alkaline phosphatase conjugated anti-mouse secondary
antibody. Antibody binding was detected using Western blue (Promega)
colorimetric substrate.
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size, which would require active transport to move into and
out of the nucleus. Full-length and smaller regions of vpx
(Fig. 1A) were inserted at the 3 end of the lacZ gene in a
eukaryotic expression vector pCR3.1 (Invitrogen). The nu-
clear localization signal (NLS) of the large T antigen of
SV40 was used as a positive control. Expression of these
-gal–Vpx fusion proteins was detected by Western blot of
transiently transfected 293T cells using an anti--gal mono-
clonal antibody (Promega) (Fig. 1B). All proteins were of
the predicted size.
Amino acids 61 to 75 of Vpx facilitate nuclear
localization of heterologous proteins
The localization of the -gal fusions was first assessed
by immunofluorescence microscopy of transiently trans-
fected HeLa cells using an anti--gal antibody (Promega),
followed by a FITC-conjugated secondary antibody (Fig. 2).
-Gal alone localized exclusively to the cytoplasm of cells
and, as expected, the lacZ-NLS positive control was ob-
served exclusively in the nuclei of transfected cells. The
fusion containing full-length Vpx was also observed to have
a predominantly nuclear phenotype. Analysis of the -gal
fusion containing partial fragments of Vpx (-gal:61–112,
-gal:61–79) indicated that amino acids 61–79 conferred a
predominantly nuclear phenotype similar to full-length
Vpx. However, fusion proteins lacking this region (e.g.,
-gal:1–60, -gal:86–112) demonstrated diffuse cellular
staining or only cytoplasmic localization. These findings are
consistent with a previous report by Mahalingam et al.
demonstrating that aa 60–85 contained a transferable NLS
(Mahalingam et al., 2001). Further dissection of this region
with overlapping Vpx regions (aa 61–72, 65–75, 69–79)
demonstrated that both aa 61–72 and aa 65–75 conferred a
predominantly nuclear phenotype, suggesting that the over-
lapping region (residues 65–72) contained an NLS.
To confirm the immunofluorescence data, cells tran-
siently transfected with the lacZ–vpx expression plasmids
were fractionated and -gal assays were performed to de-
termine the level of activity in the nuclear and cytoplasmic
compartments. Separation of the cytoplasmic and nuclear
extracts was confirmed by the lack of detection of the
cytoplasmic protein lactate dehydrogenase (LDH) in the
nuclear fraction (data not shown). The -gal results were
expressed as a ratio of the nuclear to cytoplasmic (N/C)
activity. Therefore, a ratio  1.0 would indicate a predom-
inantly nuclear protein. Indeed, the N/C ratio of the -gal-
NLS positive control was 7.0. The N/C ratio for -gal
alone was 1.0 (Fig. 3), which is defined as cytoplasmic in
this assay. Indeed, those fusion proteins observed to be
cytoplasmic by immunofluorescence all exhibited a N/C
ratio of 0.84–1.43. In contrast, all fusion proteins that con-
Fig. 2. Subcellular localization of -gal–Vpx fusion proteins. -gal–Vpx fusion proteins were detected in transiently transfected HeLa cells by indirect
immunofluorescence as described under Materials and methods. The regions of Vpx contained in each fusion are given. Nuclei were visualized by staining
with DAPI and are shown in panels to the right of the immunofluorescence images.
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tained Vpx amino acid residues 65–72 exhibited a N/C ratio
 2.0, confirming the results observed with the immuno-
fluorescence. However, the ratios of the fusions that con-
tained smaller fragments of Vpx were reduced in compari-
son to the full-length -gal–Vpx fusion, suggesting other
regions of Vpx may enhance nuclear localization or reten-
tion.
Alanine scanning mutagenesis of Vpx nuclear localization
Amino acids 65 to 72 are highly conserved among HIV-2
and SIV strains. This region contains several tyrosine resi-
dues and two basic residues (K68 and R70). To further
analyze the nuclear targeting potential of this region, we
constructed several pEGFP-Vpx clones with alanine substi-
tutions in this region and assessed their cellular localization
in transient transfection assays (Fig. 4). Alanine substitution
of the two serines at positions 63 and 65 did not impair
nuclear targeting of the fusion protein. However, alanine
substitution of the two basic residues alone (A68,70) or
together with the tyrosine residues (A66,68–71) abolished
nuclear targeting of the fusion proteins, indicating that these
two residues are critical for nuclear targeting of the fusion
protein. These results further suggest that aa 65–72 of Vpx
is an NLS. We had previously constructed several alanine-
scanning mutants of Vpx in the context of a molecular clone
(Jin et al., 2001). Two of these mutants (A74–80 and
A80–86) were cloned into the GFP fusion vector and their
localization was assessed by fluorescence microscopy. Both
mutants produced interesting phenotypes. The mutant with
alanine substitutions of aa 74 to 80 (A74–80) displayed a
predominantly cytoplasmic phenotype compared to wild-
type GFP-Vpx, suggesting this region is also important for
nuclear localization of Vpx. Another mutant, with alanine
substitutions of aa 80–86 (A80–86), while able to enter the
nucleus of cells, appeared to accumulate on the nuclear
membrane, suggesting a partial defect in nuclear transloca-
tion. These data are consistent with previous work from our
laboratory and others that identified numerous mutations
C-terminal to aa 65–72 that disrupted nuclear targeting of
Vpx (Mahalingam et al., 2001; Pancio et al., 2000).
Membrane transport and subsequent packaging of Vpx
into virions require an interaction with the p6 region of Gag.
To assess the membrane transport capability of each alanine
scanning mutant, we cotransfected each GFP-Vpx mutant
plasmid with a HIV-2 Gag-Pol plasmid (pTM-GP2) ex-
pressed by the T7-vaccinia expression system. As previ-
ously described (Pancio et al., 2000), GFP-Vpx was ob-
served at the membrane of cells when coexpressed with
Gag-Pol (Fig. 5, arrows). Alanine substitution of aa 74–80
and 80–86 had been previously shown to be deleterious to
Vpx packaging (Jin et al., 2001) and, as expected, both
mutants failed to demonstrate membrane targeting when
expressed with Gag-Pol (Fig. 5). The three other alanine
mutants (A63,65; A66,68–71; A68,70) exhibited membrane
localization similar to wild-type GFP-Vpx, indicating that
alanine substitution in this region was not deleterious to
targeting of Vpx to the membrane. Furthermore, these re-
sults demonstrate that nuclear localization and membrane
targeting are separable, but not discrete since A74–80 is
deficient for both nuclear targeting and membrane transport.
HIV-2 ROD Vpx is not a shuttling protein
Recent studies have identified HIV-1 Vpr as a shuttling
protein (Sherman et al., 2001). While the role of nuclear
export of Vpr has not been elucidated, it has been demon-
strated that shuttling is not required for packaging of Vpr,
but may be important for Vpr-mediated cell-cycle arrest
(Jenkins et al., 2001). Given the homology between Vpr and
Vpx, we therefore examined whether Vpx was a shuttling
protein. To determine whether Vpx shuttled, we used a
heterokaryon shuttling assay developed by Jenkins et al.
(2001). In this assay, HeLa cells transiently transfected with
GFP fusion proteins were plated onto mouse L cells and
treated with polyethylene glycol (PEG) to initiate cell fu-
sion. Cells were washed and incubated for an additional 3 h
in the presence of cycloheximide. Cells were fixed and
permeabilized, and nuclei were stained with DAPI. DAPI
staining of L cells results in nuclei with bright, punctate,
foci that are easily distinguishable from the HeLa cell nuclei
(Fig. 6, right panel, denoted with arrows). Shuttling can be
observed under a fluorescence microscope by the movement
of the GFP fusion protein to the L cell nuclei. For our
Fig. 3. -gal–Vpx fusions containing Vpx aa 65 to 72 localize primarily to
the nucleus of transfected cells. 293T cells transiently transfected with the
indicated expression vectors were fractionated and the -gal activity was
determined for the cytoplasmic and nuclear fractions. Separation of the
cytoplasmic and nuclear fractions was monitored by detection of the
cytoplasmic LDH protein in the nuclear fraction using a commercially
available kit (Sigma). Results are expressed as the ratio of nuclear to
cytoplasmic (N/C) activity of the -gal–Vpx fusion proteins. Error bars
denote the standard error of the mean.
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studies, a GFP–HIV-1 Vpr fusion protein was used as a
positive control, which was observed in the L cell nuclei
(Fig. 6). GFP-HIV-2 Vpx, however, did not move into the L
cell nuclei when tested, indicating that shuttling did not
occur. Transient transfection of GFP-HIV-2 Vpx into L
cells alone produced a nuclear phenotype, confirming that
the absence of GFP-HIV-2 Vpx in the L cell nuclei in the
fusion assays was due to an absence of nuclear export from
the HeLa cell nuclei and not a failure of nuclear import into
L cells (data not shown). We also assessed whether a GFP–
HIV-2 Vpr fusion protein could shuttle (Fig. 6). Similar to
HIV-1 Vpr, the GFP–HIV-2 Vpr protein was able to trans-
locate from the HeLa nuclei to the L cell nuclei. The lack of
shuttling of Vpx is consistent with the hypothesis that the
shuttling of HIV-1 and HIV-2 Vpr is not required for virion
incorporation or PIC import, but rather may be important for
another function of Vpr, such as cell-cycle arrest.
Discussion
Nuclear localization of HIV-2 Vpx is necessary for the
import of the viral preintegration complex into the nucleus
of nondividing cells (Fletcher et al., 1996; Pancio et al.,
2000). Studies by Mahalingham et al. had identified an NLS
within aa 60–85 of Vpx and demonstrated that several
residues within this region were critical for Vpx nuclear
localization and virus replication in nondividing cells (Ma-
Fig. 4. Alanine substitution of critical residues abolishes GFP–Vpx nuclear localization. Epifluorescence images of HeLa cells transiently transfected with
GFP–Vpx fusion proteins containing the indicated alanine substitutions. After fixation, cells were permeabilized and nuclei were stained with DAPI (right
panels).
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halingam et al., 2001). The current studies have extended
this work and identified a minimal transferable nuclear
localization signal of HIV-2 Vpx to aa 65–72 (. . .SYT-
KYRYL. . .). This stretch of amino acids is highly con-
served among HIV-2/SIV strains, further suggestive of the
importance of this region. Classical NLSs are commonly
either monopartite or bipartite. Monopartite NLSs are char-
acterized by a single stretch of three or more basic residues,
whereas bipartite NLSs are composed of two stretches of
basic residues separated by approximately 10 amino acids.
The Vpx NLS has two basic residues (K68 and R70) and
several tyrosines, but lacks a run of basic residues homol-
ogous to the classical monopartite NLS. Similarly, analysis
of the surrounding amino acids failed to identify a motif
consistent with a bipartite NLS. However, alanine substitu-
tion of K68 and R70 abolished nuclear localization of GFP-
Vpx, demonstrating that the basic residues are critical com-
ponents of the Vpx NLS. Therefore, given the absence of
either a classical monopartite or bipartite NLS, it is likely
that Vpx may require novel protein–protein interactions to
move across the nuclear pore.
Although previous studies (Mahalingam et al., 2001;
Pancio et al., 2000) have demonstrated that mutations C-
terminal to the NLS are deleterious to Vpx nuclear local-
ization, we were able to map an NLS to a 10-aa region.
However, the functional - gal fractionation data would
suggest that only full-length Vpx maintains complete nu-
clear import capability. There are several possibilities to
explain this discrepancy. The most obvious explanation is
that the mutations/deletions that have been previously re-
ported may alter Vpx structure such that the NLS is com-
promised and no longer completely functional. A second
possibility is that the C-terminal mutations disrupt another
function of Vpx required for full nuclear import capability.
Further studies would be needed to characterize the C-
terminus of Vpx and identify any novel functional domains
that affect the nuclear transport of Vpx. A third theory to
explain this discrepancy could be the presence of a second
NLS, such as demonstrated for HIV-1 Vpr (Jenkins et al.,
1998). However, we feel that the broad panel of -gal–Vpx
fusions we tested would have likely identified a second
NLS, if present. Finally, it could also be possible that -gal
may have compensated for a domain in Vpx to facilitate
nuclear import. -Gal may have provided a domain in trans
to enhance a weak NLS in the smaller fusion proteins.
Alternatively, since -gal exists as a tetramer in vivo, the
protein could have enhanced nuclear targeting of the smaller
fusions by multiplying the effect of a single, weak NLS.
Therefore, a tetramer of fusion proteins containing four
weak NLSs would appear to have stronger karyophilic prop-
Fig. 5. Membrane targeting of GFP–Vpx alanine mutants. U87 cells were
infected/transfected as described under Materials and methods with the
indicated GFP–Vpx expression plasmids with or without the GagPol ex-
pression plasmid pTM-GP2. Sixteen hours later cells were fixed and
mounted, and images were obtained. Membrane localization is denoted by
arrows.
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erties. Nevertheless, while a larger domain of Vpx may be
necessary for full function, our results demonstrate that aa
65–72 are residues critical for the karyophilic properties of
HIV-2 Vpx.
In the presence of Gag, Vpx is trafficked to the plasma
membrane via an interaction with p6 (Selig et al., 1999).
Previous work demonstrated that mutation of aa 74–86 of
Vpx reduced Vpx incorporation into virus-like particles and
aa 80–86 were important for Vpx–Gag interactions (Jin et
al., 2001). Consistent with these findings, alanine substitu-
tion of aa 74–80 or 80–86 abolished membrane transport
of GFP-Vpx fusions. The alanine substitution of K68 and
R70 abolished nuclear localization of GFP- Vpx, but had no
effect on Vpx membrane transport, demonstrating that the
nuclear localization and membrane transport functions are
separable within Vpx. Alanine substitution of aa 74–80,
however, was deleterious to both nuclear localization and
membrane transport, indicating that these functional do-
mains are not discrete. These findings support a model of
Vpx transport whereby the interaction of Vpx with the p6
region of Gag suppresses the NLS of Vpx to target Vpx to
the plasma membrane of cells for incorporation into virions.
The functions of HIV-1 Vpr are shared between HIV-2
Vpr and Vpx. Both proteins are packaged into virions and
associate with the reverse transcription complex early after
infection of cells (Fletcher et al., 1996); however, only Vpx
is thought to play a role in PIC nuclear import (Fletcher et
al., 1996). Recently, HIV-1 Vpr was identified as a shuttling
Fig. 6. HIV-2 Vpx does not shuttle. HeLa cells were transiently transfected with the indicated GFP fusion plasmids 18 h prior to being plated onto L cells.
After allowing the HeLa cells to settle, the cells were fused with PEG, washed, and incubated an additional 3 h in the presence of cycloheximide. Cells were
fixed, permeabilized, and stained with DAPI (right panels). L cells stained with DAPI (denoted with arrows) exhibit a bright, punctate staining in comparison
to HeLa cells. Shuttling is demonstrated by the movement of the GFP fusion protein into the L cell nuclei.
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protein (Sherman et al., 2001). Although the functional
significance of HIV-1 Vpr shuttling is not clear, it has been
demonstrated that HIV-1 Vpr shuttling is not necessary for
packaging into virions (Jenkins et al., 2001). Our studies
indicated that HIV-2 Vpr, but not Vpx, is a shuttling protein.
The inability of HIV-2 Vpx to shuttle is consistent with the
idea that shuttling is not necessary for the packaging of
Vpr/Vpx proteins (Jenkins et al., 2001). Furthermore, the
inability of Vpx to shuttle suggests that shuttling plays no
role in the nuclear import of the HIV-2 PIC. Rather, since
HIV-2 Vpr shuttles, it would seem likely that shuttling is
important for Vpr-mediated G2 cell-cycle arrest or another
undefined function.
We have identified a minimal NLS of HIV-2 Vpx; how-
ever, questions still remain to define the exact role of Vpx
in PIC nuclear import. The lack of a “classical” NLS sug-
gests that Vpx may use a novel pathway to access the nuclei
of cells. Future studies to identify cellular proteins that
interact with Vpx will further define the pathway through
which Vpx accesses the nucleus and the role the Vpx pro-
tein plays as a component of the HIV-2 PIC. Delineation of
the role the Vpx/Vpr proteins play in the nuclear import of
the PIC may lead to the development of novel therapeutic
interventions of HIV infection.
Materials and methods
Plasmid construction
Plasmids pTM-GP2 and pEGFPVpx have been previ-
ously described (Horton et al., 1994; Pancio et al., 2000). To
construct lacZ fusions, the lacZ ORF was PCR amplified
from pCH110 (Amersham Biosciences, Piscataway, NJ)
using Redi-Taq as described by the manufacturer (Sigma-
Aldrich, St. Louis, MO). Primer sequences are available
upon request. The 3 primer in the reaction contained an
artificial XhoI restriction site inserted immediately 5 of the
stop codon. The PCR product was TA cloned into
pcDNA3.1/V5-His-TOPO as described by the manufacturer
(Invitrogen, Carlsbad, CA). Positive clones (pclacZ(XhoI))
were identified by restriction mapping and sequencing the
5 and 3 insert junctions. All vpx inserts for fusion vectors
were cloned into the XhoI site of the plasmid. For full-length
and larger segments of vpx, regions were PCR amplified
with HIV-2 ROD-specific PCR primers containing XhoI
sites on both 5 and 3 primers, with premature stop codons
in the 3 primers of truncated fragments. For regions of 12
aa or less, overlapping primers were synthesized (IDT Tech-
nologies, Iowa City, IA), annealed, phosphorylated, and
ligated into digested pclacZ(XhoI). All clones were con-
firmed by sequence analysis. Alanine substitutions were
inserted into pEGFP-Vpx by Excite Mutagenesis (Strat-
agene, La Jolla, CA) as described by the manufacturer using
primers with site-specific substitutions. Alanine substitu-
tions were confirmed by sequence analysis.
Fractionation assays
293T cells were maintained in Dulbecco’s modified Ea-
gle’s medium supplemented with 10% fetal calf serum and
penicillin/streptomycin. Cells were transfected using
TransIT-LT1 reagent with 2–4 g of indicated lacZ-fusion
plasmids as described by the manufacturer (PanVera, Mad-
ison, WI). Forty-eight hours posttransfection, cells were
harvested by treatment with PBS  5 mM EDTA and
transferred to 1.5 mL microcentrifuge tubes. Nuclear and
cytoplasmic fractions were obtained using a commercially
available kit (Pierce Chemical Co., Rockford, IL). Separa-
tion of the fractions was confirmed by lack of detectable
LDH enzyme in the nuclear fractions using a commercially
available kit (Sigma-Aldrich). Protein concentrations of
each fraction were determined using a commercially avail-
able kit (Pierce Chemical Co.). The enzymatic activity of
the -gal fusion was determined using a colorimetric mi-
crotiter plate assay. Results are presented as a ratio of the
nuclear to cytoplasmic -gal activity. The results for each
fusion represent at least three independent experiments,
with three separate transfections per experiment.
Immunofluorescence analysis
HeLa cells (5  105) seeded onto glass coverslips were
transfected with 2 g of lacZ fusion expression plasmids as
described above and incubated overnight. Cells were
washed, fixed with 4% paraformaldehyde in PBS, washed
again, and then permeabilized with 0.2% Triton X-100 in
PBS for 5 min. -Gal was detected using a monoclonal
antibody (Promega), followed by a FITC-conjugated anti-
mouse IgG secondary antibody (Sigma). After the antibody
incubations, the cells were incubated for 5 min with 2
g/mL DAPI to allow for visualization of nuclei. Cells were
visualized and images obtained using a fluorescence micro-
scope equipped with an Optronics Magnafire imaging sys-
tem (Optronics, Goleta, CA). Multiple images were ob-
tained from at least two independent transfections and
images presented in figures are representative of the domi-
nant phenotype observed.
GFP-Vpx mutant localization and membrane transport
assays
U87 cells maintained in DMEM supplemented with 15%
FBS and penicillin/streptomycin were plated onto glass cov-
erslips in six-well plates. For localization assays, HeLa cells
were transfected with 2 g of indicated expression plasmid
as described above. For membrane transport assays, U87
cells were infected with VPT7-3 vaccinia virus for 1 h in
OptiMEM (Invitrogen) and then transfected in normal me-
dia with 2 g of indicated GFP-Vpx mutant or 1 g GFP-
Vpx mutant, and 1 g pTM-GP2. U87 cells were grown
overnight, fixed with 4% paraformaldehyde in PBS, washed
3 in PBS  1% FBS, and mounted onto slides. For
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localization studies, HeLa cells were permeabilized with
0.2% Triton X-100 for 5 min after fixation and washed, and
nuclei were stained with 2 g/mL DAPI and washed again
prior to mounting. Slides were visualized and multiple im-
ages obtained as described above. Images presented in fig-
ures are representative of the dominant phenotype for each
mutant.
Heterokaryon shuttling assays
HeLa and L cells were maintained as described above.
HeLa cells (5 105) were seeded into one well of a six-well
plate and the next day were transfected with 2 g of GFP-
fusion plasmid. That same day, L cells were seeded onto
coverslips in six-well plates at a density of 5  105 cells/
well. The next day, the HeLa cells were trypsinized and
plated onto the L cells. After allowing the HeLa cells to
settle (3–5 h), the coverslips were removed and inverted
onto 50% w/v PEG (Sigma-Aldrich) for 2 min to initiate
cell–cell fusion. The cells were then washed with PBS and
incubated for an additional 2 h in media containing 50
g/mL cycloheximide. Cells were fixed, permeabilized,
stained with DAPI, and mounted, and images were obtained
as described above.
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